Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades

Abstract This study investigated treatment characteristics of Guillain-Barré syndrome (GBS) in a real-world setting between 2000 and 2019. We analyzed clinical improvement between nadir and last follow-up in patients with severe GBS (defined as having a GBS disability scale > 2 at nadir) and aime...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jakob Rath, Gudrun Zulehner, Bernadette Schober, Anna Grisold, Martin Krenn, Hakan Cetin, Fritz Zimprich
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3973d21d9d3743acb19dd9273c18c1c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3973d21d9d3743acb19dd9273c18c1c1
record_format	dspace
spelling	oai:doaj.org-article:3973d21d9d3743acb19dd9273c18c1c12021-12-02T19:16:54ZReal-world treatment of adult patients with Guillain-Barré syndrome over the last two decades10.1038/s41598-021-98501-y2045-2322https://doaj.org/article/3973d21d9d3743acb19dd9273c18c1c12021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98501-yhttps://doaj.org/toc/2045-2322Abstract This study investigated treatment characteristics of Guillain-Barré syndrome (GBS) in a real-world setting between 2000 and 2019. We analyzed clinical improvement between nadir and last follow-up in patients with severe GBS (defined as having a GBS disability scale > 2 at nadir) and aimed to detect clinical factors associated with multiple treatments. We included 121 patients (74 male; median age 48 [IQR 35–60]) with sensorimotor (63%), pure motor (15%), pure sensory (10%) and localized GBS (6%) as well as Miller Fisher syndrome (6%). 44% of patients were severely affected. All but one patient received at least one immunomodulatory treatment with initially either intravenous immunoglobulins (88%), plasma exchange (10%) or corticosteroids (1%), and 25% of patients received more than one treatment. Severe GBS but not age, sex, GBS subtype or date of diagnosis was associated with higher odds to receive more than one treatment (OR 4.22; 95%CI 1.36–13.10; p = 0.01). Receiving multiple treatments had no adjusted effect (OR 1.30, 95%CI 0.31–5.40, p = 0.72) on clinical improvement between nadir and last follow-up in patients with severe GBS. This treatment practice did not change over the last 20 years.Jakob RathGudrun ZulehnerBernadette SchoberAnna GrisoldMartin KrennHakan CetinFritz ZimprichNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jakob Rath Gudrun Zulehner Bernadette Schober Anna Grisold Martin Krenn Hakan Cetin Fritz Zimprich Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades
description	Abstract This study investigated treatment characteristics of Guillain-Barré syndrome (GBS) in a real-world setting between 2000 and 2019. We analyzed clinical improvement between nadir and last follow-up in patients with severe GBS (defined as having a GBS disability scale > 2 at nadir) and aimed to detect clinical factors associated with multiple treatments. We included 121 patients (74 male; median age 48 [IQR 35–60]) with sensorimotor (63%), pure motor (15%), pure sensory (10%) and localized GBS (6%) as well as Miller Fisher syndrome (6%). 44% of patients were severely affected. All but one patient received at least one immunomodulatory treatment with initially either intravenous immunoglobulins (88%), plasma exchange (10%) or corticosteroids (1%), and 25% of patients received more than one treatment. Severe GBS but not age, sex, GBS subtype or date of diagnosis was associated with higher odds to receive more than one treatment (OR 4.22; 95%CI 1.36–13.10; p = 0.01). Receiving multiple treatments had no adjusted effect (OR 1.30, 95%CI 0.31–5.40, p = 0.72) on clinical improvement between nadir and last follow-up in patients with severe GBS. This treatment practice did not change over the last 20 years.
format	article
author	Jakob Rath Gudrun Zulehner Bernadette Schober Anna Grisold Martin Krenn Hakan Cetin Fritz Zimprich
author_facet	Jakob Rath Gudrun Zulehner Bernadette Schober Anna Grisold Martin Krenn Hakan Cetin Fritz Zimprich
author_sort	Jakob Rath
title	Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades
title_short	Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades
title_full	Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades
title_fullStr	Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades
title_full_unstemmed	Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades
title_sort	real-world treatment of adult patients with guillain-barré syndrome over the last two decades
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3973d21d9d3743acb19dd9273c18c1c1
work_keys_str_mv	AT jakobrath realworldtreatmentofadultpatientswithguillainbarresyndromeoverthelasttwodecades AT gudrunzulehner realworldtreatmentofadultpatientswithguillainbarresyndromeoverthelasttwodecades AT bernadetteschober realworldtreatmentofadultpatientswithguillainbarresyndromeoverthelasttwodecades AT annagrisold realworldtreatmentofadultpatientswithguillainbarresyndromeoverthelasttwodecades AT martinkrenn realworldtreatmentofadultpatientswithguillainbarresyndromeoverthelasttwodecades AT hakancetin realworldtreatmentofadultpatientswithguillainbarresyndromeoverthelasttwodecades AT fritzzimprich realworldtreatmentofadultpatientswithguillainbarresyndromeoverthelasttwodecades
_version_	1718376905803038720

Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades

Ejemplares similares